Blueberry Therapeutics’ CEO, Dr. John Ridden sat down with Pharmaphorum’s Dominic Tyer to talk strategy and bringing innovation to life through Blueberry Therapeutics’ nanomedicine approach. Dr. Ridden also spoke about the concept of risk management in small biotech companies and the latest funding deal with China Medical Venture Investment (CMS).
Listen to the podcast here: https://pharmaphorum.com/r-d/biotech-strategy-and-nanomedicine/